Comparing ASK0912 to polymyxin B for hospital-acquired pneumonia
This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pneumonia that started during a hospital stay or while on a breathing machine.
- You have at least one symptom of pneumonia (like fever, cough, or difficulty breathing) and at least one abnormal lab test (like high white blood cell count).
- A chest X-ray or CT scan shows new or worsening signs of pneumonia.
- You are not allergic to polymyxin or carbapenem antibiotics.
- You have not received antibiotics for this pneumonia for more than 24 hours in the last 3 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This trial tests a new antibiotic called HRS-8427 for adults with bacterial pneumonia that started in the hospital or while on a ventilator. It may be an option if you need IV antibiotics and haven't already received long-term treatment for this infection.
This trial tests a new antibiotic called YK-1169 compared to a standard antibiotic (ceftazidime-avibactam) in adults with serious lung infections acquired in hospitals or from ventilators. The goal is to see if YK-1169 works as well or better at treating these infections.
This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
This trial tests a drug called Polymyxin E2 Methanesulfonate for a serious lung infection that patients can get in the hospital, caused by bacteria that don't respond to common antibiotics. It may be an option for people on ventilators or recently hospitalized with pneumonia that standard drugs can't treat.
Hear when a new Ventilator-associated Bacterial Pneumonia (VABP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.